AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31221697
Drug: GLP-1Ra treatment
RxNorm normalized name: IL-1RA
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: GLP-1Ra treatment for 3 months
Trial: 30627180
Drug: Budesonide nebulizer
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide nebulizer suspension (Pulmicort Nebulizer)
Trial: 30627180
Drug: Budesonide inhalation
RxNorm normalized name: Budesonide Inhalation Powder
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide inhalation suspension (Pulmicort Turbuhaler)
Trial: 27632179
Drug: Ezetimibe (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe (10 mg daily oral administration, n = 209)
Trial: 10229249
Drug: Intracutaneous sterile
RxNorm normalized name: Steril-Eyes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracutaneous sterile water injections (ISW)
Trial: 7890212
Drug: Gorging pattern
RxNorm normalized name: benzocaine
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gorging pattern (two meals daily)
Trial: 7890212
Drug: Nibbling pattern
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nibbling pattern (four to seven meals daily)
Trial: 1979541
Drug: Acrivastine administered
RxNorm normalized name: Acrivastine
DrugBank: Acrivastine (DB09488)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acrivastine administered 30, 45, 60 or 90 min before challenge
Trial: 30415988
Drug: Adjuvant modified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant modified FOLFIRINOX (oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, irinotecan 180 mg/m2, and 5‐FU 2.4 g/m2 over 46 hours) every 2 weeks for 24 weeks (12 cycles)
Trial: 30415988
Drug: Modified FOLFOX6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified FOLFOX6 (oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, 5‐FU bolus 400 mg/m2, then 2.4 g/m2 over 46 hours) every 2 weeks for 24 weeks (12 cycles)
Trial: 25384542
Drug: Bifocal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bifocal treatment of myopia
Trial: 18505372
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg oral clodronate (Bonefos) daily over 3 years
Trial: 15513572
Drug: Combined growth
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined growth hormone (GH) and GnRH analogue treatment
Trial: 15513572
Drug: GnRH analogue
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH analogue treatment alone
Trial: 9295978
Drug: Endoscopy at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopy at the end of initial treatment (group 1)
Trial: 9295978
Drug: No endoscopy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No endoscopy at the end of initial treatment (group 2)
Trial: 3537216
Drug: 5-day pulse
RxNorm normalized name: DULSE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-day pulse chemotherapy every 3 weeks (group I)
Trial: 3537216
Drug: Continuous chemotherapy
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous chemotherapy (group C)
Trial: 3537216
Drug: Semi-continuous chemotherapy
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Semi-continuous chemotherapy (group G)
Trial: 6366137
Drug: 3 years
RxNorm normalized name: NanoVM 1-3 years
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 years of chemotherapy
Trial: 20805344
Drug: Early class
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early class III protraction facemask treatment (PFG)
Trial: 20805344
Drug: Control/no treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control/no treatment (CG)
Trial: 18937608
Drug: Patient-controlled sedation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled sedation (PCS) with propofol bolus of 0.25 mg kg(‐1); no lockout interval; n = 50
Trial: 18937608
Drug: Anesthesiologist-controlled sedation
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anesthesiologist-controlled sedation (ACS) with continuous infusion of propofol 1% (3 mg kg(‐1) h(‐1); n = 50)
Trial: 15674406
Drug: Spironolactone (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone (25 mg/day)
Trial: 7575256
Drug: 0.3% ofloxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3% ofloxacin solution
Trial: 10707137
Drug: Fortified tobramycin
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fortified tobramycin (1.5%) and cefazolin (10%) solutions (control group)
Trial: 8550186
Drug: Monoclonal antibody
RxNorm normalized name: Monoclonal antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monoclonal antibody (MAb) 61BG 1.3, 3 micrograms per tooth, applied at 1, 3, 7, and 10 days after suppression of P. gingivalis.
Trial: 8550186
Drug: Monoclonal antibody
RxNorm normalized name: Monoclonal antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monoclonal antibody (MAb) 61BG 1.3
Trial: 1841774
Drug: High-dose verapamil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose verapamil treatment (Isoptin RR, 240 mg verapamil, twice daily)
Trial: 6138074
Drug: Vesparax (barbiturate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vesparax (barbiturate combination)
Trial: 31172446
Drug: GDC-0276 single
RxNorm normalized name: GDC-0425
DrugBank: GDC-0425 (DB14791)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GDC-0276 single doses (SD) of 2–270 mg (PIC) and 45–540 mg (CD)
Trial: 31172446
Drug: GDC-0276 multiple
RxNorm normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GDC-0276 multiple doses (MD) of 15–540 mg divided into two or three doses/day
Trial: 26879545
Drug: Intraperitoneal paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intraperitoneal paclitaxel (PTX) at 60 mg/m2 on the day of surgery and on days 14, 21, 28, 42, 49, and 56
Trial: 26879545
Drug: Intravenous paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous paclitaxel (PTX) at 80 mg/m2 on the same schedule
Trial: 25703611
Drug: Virtual reality
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virtual reality exposure therapy for PTSD
Trial: 16917560
Drug: Amoxicillin/Clavulanate
RxNorm normalized name: AMOXICILLIN/CLAVULANATE
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin/Clavulanate
Trial: 12791225
Drug: Topical ophthalmic
RxNorm normalized name: MIOTICS,TOPICAL OPHTHALMIC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ophthalmic NSAIDs
Trial: 8915645
Drug: ADCON-L Anti-Adhesion
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADCON-L Anti-Adhesion Barrier Gel
Trial: 1871184
Drug: Evening primrose
RxNorm normalized name: EVENING PRIMROSE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evening primrose oil (EPO) supplementation (45 mg GLA and 360 mg linoleic acid, 2 capsules daily for 4 months, then 4 capsules daily for 4 months)
Trial: 6137500
Drug: Prazosin (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazosin (4 mg, 2 pills of Minipress Pfizer per day) for 7 days
Trial: 31425171
Drug: Pharmacist-led hypertension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist-led hypertension management program with barbers promoting follow-up and pharmacists prescribing antihypertensive therapy.
Trial: 27779354
Drug: Parecoxib 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parecoxib 0.25 mg·kg‐1
Trial: 27779354
Drug: Parecoxib 1
RxNorm normalized name: Parécoxib
DrugBank: Parecoxib (DB08439)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Parecoxib 1 mg·kg‐1
Trial: 27779354
Drug: Parecoxib 2
RxNorm normalized name: parecoxib 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parecoxib 2 mg·kg‐1
Trial: 27779354
Drug: Parecoxib (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parecoxib (various doses)
Trial: 23486511
Drug: Whey protein
RxNorm normalized name: Whey protein
DrugBank: Whey (DB18685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey protein (20 g)
Trial: 23909813
Drug: Glucose (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose (10 g)
Trial: 24314863
Drug: Glucose (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose (20 g)
Trial: 17994473
Drug: Intranasal cocaine
RxNorm normalized name: Cocaine
DrugBank: Cocaine (DB00907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal cocaine (4, 20, 40, and 60 mg) during aripiprazole maintenance
Trial: 16400891
Drug: Epinephrine (2,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epinephrine (2, 4, and 8 actuations administered at 17‐minute intervals)
Trial: 16400891
Drug: Albuterol (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol (6 cumulative actuations administered at 17‐minute intervals)
Trial: 16310974
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment plus contingency management (CM)
Trial: 8573426
Drug: Tiludronate 400
RxNorm normalized name: tiludronate
DrugBank: Tiludronic acid (DB01133)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tiludronate 400 mg/day for 3 months
Trial: 12669742
Drug: Etidronate 400
RxNorm normalized name: etidronate 400 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etidronate 400 mg/day
Trial: 2229455
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg velnacrine tid for 28 days
Trial: 2229455
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg velnacrine bid
Trial: 2229455
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg velnacrine bid
Trial: 2229455
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg velnacrine bid
Trial: 29431126
Drug: Sham rTMS
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham rTMS treatment (Control)
Trial: 26056438
Drug: Low-threshold physical
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-threshold physical activity program (60 minutes weekly for 20 weeks)
Trial: 22680774
Drug: Intensive chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive chemotherapy (i.v., mg/m(2), vindesine 5, adriamycin 90, BCNU 140, etoposide 600, methylprednisolone 600) before radiotherapy (RT)
Trial: 22232850
Drug: Etoricoxib 60
RxNorm normalized name: etoricoxib 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoricoxib 60 mg (test product: Etocox-60)
Trial: 22232850
Drug: Etoricoxib 60
RxNorm normalized name: etoricoxib 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoricoxib 60 mg (reference product)
Trial: 22232850
Drug: Etoricoxib 60
RxNorm normalized name: etoricoxib 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoricoxib 60 mg (test product: Etocox-60) and reference product
Trial: 19770831
Drug: Cavinton 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cavinton 30 mg/day for 90 days (2 courses per year) in addition to basic therapy
Trial: 19770831
Drug: Cavinton treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cavinton treatment
Trial: 12044619
Drug: Sustained-release morphine
RxNorm normalized name: morphine Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release morphine (20mg/d titrated to a maximum of 180mg/d)
Trial: 7842195
Drug: Both therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both therapies (Oxygen and Dopamine)
Trial: 731810
Drug: estramustine-17-phosphate (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: estramustine-17-phosphate (600 mg daily for at least 3 months)
Trial: 731810
Drug: 2.6‐cis-diphenylhexamethylcyclotetrasiloxane (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.6‐cis-diphenylhexamethylcyclotetrasiloxane (300 mg daily for at least 3 months)
Trial: 29398993
Drug: Pregabalin 150
RxNorm normalized name: pregabalin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin 150 mg daily
Trial: 25295709
Drug: Procalcitonin (PCT)
RxNorm normalized name: Procalcitonin
DrugBank: Procalcitonin (DB14812)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Procalcitonin (PCT) algorithm with 0.1 ng/ml cut-off
Trial: 23623623
Drug: In-Home Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-Home Cognitive Behavioral Therapy (IH-CBT)
Trial: 18548362
Drug: Beta-alanine (4.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-alanine (4.8 g per day)
Trial: 15706558
Drug: Whole body
RxNorm normalized name: MaxiVision Whole Body Formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole body vibration plus physical therapy (PT)
Trial: 7698053
Drug: 9 g
RxNorm normalized name: Publix Pen Needle 29 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9 g of fish oil
Trial: 7698053
Drug: 18 g
RxNorm normalized name: flotufolastat F 18 gallium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18 g of fish oil
Trial: 7698053
Drug: 9 g
RxNorm normalized name: Publix Pen Needle 29 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9 g of corn oil
Trial: 7698053
Drug: 18 g
RxNorm normalized name: flotufolastat F 18 gallium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18 g of corn oil
Trial: 2655680
Drug: Intravenous methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous methylprednisolone sodium succinate (MPSS) at doses of 20, 40, and 80 mg
Trial: 2655680
Drug: Oral methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral methylprednisolone (20 mg as 4 x 5 mg tablets)
Trial: 31285821
Drug: WHO EBHR
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: WHO EBHR formulation with 0.5% glycerol
Trial: 31285821
Drug: WHO EBHR
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: WHO EBHR formulation without glycerol (0%)
Trial: 31285821
Drug: WHO EBHR
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: WHO EBHR formulation with 1.45% glycerol
Trial: 31285821
Drug: WHO EBHR
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: WHO EBHR formulation with 0.75% glycerol
Trial: 27831503
Drug: cisplatin-paclitaxel (chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cisplatin-paclitaxel (chemotherapy group)
Trial: 17518508
Drug: Cinacalcet (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinacalcet (90 mg) alone
Trial: 17518508
Drug: Cinacalcet (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinacalcet (90 mg) with ketoconazole (200 mg twice daily for 7 days)
Trial: 17518508
Drug: Cinacalcet (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinacalcet (90 mg) with ketoconazole
Trial: 12628619
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for nicotine dependence
Trial: 9879639
Drug: 14C-delmopinol mouth
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14C-delmopinol mouth rinse (10-ml aqueous solution at 2 mg/ml)
Trial: 9879639
Drug: 14C-delmopinol oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14C-delmopinol oral dose
Trial: 31742932
Drug: Propel steroid
RxNorm normalized name: Propel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propel steroid eluting stents (packing type B)
Trial: 20141367
Drug: Alendronate 70
RxNorm normalized name: ALENDRONATE 70MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate 70 mg once weekly for 1 year
Trial: 20141367
Drug: Risedronate 35
RxNorm normalized name: risedronate 35 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate 35 mg once weekly for 1 year
Trial: 10969426
Drug: Weekly home-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly home-based intervention
Trial: 10969426
Drug: Control (brief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (brief monthly tracking visits)
Trial: 9102666
Drug: Multiple insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multiple insulin therapy
Trial: 8416458
Drug: Amoxicillin 3
RxNorm normalized name: amoxicillin 375 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin 3 g orally plus probenecid 1 g orally
Trial: 6134959
Drug: Spectinomycin 2
RxNorm normalized name: spectinomycin 2 g intramuscular powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spectinomycin 2 g IM
Trial: 2877490
Drug: Colloidal bismuth
RxNorm normalized name: Colloidal bismuth subcitrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colloidal bismuth subcitrate (CBS), 120 mg 4 times a day
Trial: 2877490
Drug: Cimetidine (C),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (C), 400 mg 3 times a day
Trial: 2877490
Drug: Cimetidine (C),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (C), 400 mg at meals plus 800 mg at bedtime
Trial: 30173431
Drug: 100 U
RxNorm normalized name: vitamin E 100 UNT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 U botulinum‐A toxin at 10 U/ml
Trial: 30173431
Drug: 100 U
RxNorm normalized name: vitamin E 100 UNT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 U botulin‐A toxin at 10 U/ml
Trial: 22712629
Drug: Memantine 5
RxNorm normalized name: memantine 5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Memantine 5 mg once daily, titrated to 10 mg twice daily for 11 days, then DMQ 30 mg every 12 hours for 8 days
Trial: 22712629
Drug: DMQ 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMQ 30 mg every 12 hours for 8 days, then memantine titrated to 10 mg every 12 hours for 11 days
Trial: 18587135
Drug: IL-2 at
RxNorm normalized name: IL-2
DrugBank: Human interleukin-2 (DB14865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL-2 at 4.5 MIU twice daily in 5 day cycles
Trial: 18587135
Drug: IL-2 at
RxNorm normalized name: IL-2
DrugBank: Human interleukin-2 (DB14865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL-2 at 7.5 MIU twice daily in 5 day cycles
Trial: 10663618
Drug: High-dose IL-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose IL-2
Trial: 11788552
Drug: 500 ml
RxNorm normalized name: TPN Bag 500 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 ml meat soup meal
Trial: 9895382
Drug: PEG (13
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG (13 g/sachet)
Trial: 9895382
Drug: Lactulose (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactulose (10 g/sachet)
Trial: 8562673
Drug: 0.8 ml/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8 ml/kg alcohol
Trial: 2371929
Drug: Sodium citrate
RxNorm normalized name: Sodium Citrate
DrugBank: Sodium nitrate (DB15952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium citrate (30 ml)
Trial: 7395881
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of lidocaine or placebo
Trial: 31987229
Drug: 500 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg/day of synbiotic for 8 weeks
Trial: 31407653
Drug: Annual community-wide
RxNorm normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Annual community-wide treatment (CWT) for four years
Trial: 31407653
Drug: Biennial school-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biennial school-based treatment (SBT) over four years
Trial: 28300854
Drug: THVD-102 (oxybutynin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THVD-102 (oxybutynin 7.5 mg / pilocarpine 7.5 mg)
Trial: 15605184
Drug: IV/PO moxifloxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV/PO moxifloxacin (400 mg q.i.d.)
Trial: 15605184
Drug: IV/PO antimicrobial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV/PO antimicrobial comparator agents
Trial: 9005910
Drug: Postoperative epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative epidural infusion of 5 microg/ml fentanyl
Trial: 9005910
Drug: Postoperative epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative epidural infusion of 5 microg/ml fentanyl plus 0.125% bupivacaine at a rate of 10 ml per hour
Trial: 31229619
Drug: Oral GABA
RxNorm normalized name: GABA
DrugBank: gamma-Aminobutyric acid (DB02530)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral GABA twice daily plus two injections of recombinant GAD enzyme
Trial: 31229619
Drug: Oral GABA
RxNorm normalized name: GABA
DrugBank: gamma-Aminobutyric acid (DB02530)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral GABA plus placebo GAD injections
Trial: 29485791
Drug: IV‐PCA with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV‐PCA with morphine
Trial: 15657666
Drug: PTP injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTP injection into intersphincteric space and internal anal sphincter with guidance by endoanal ultrasound (Group A, n = 42)